Treatment of hypertension with a very low dose of antibody to C-fragment of type 1 angiotensin II receptor
https://doi.org/10.18705/1607-419X-2008-14-3-236-238
Abstract
The study documented blood pressure lowering effect according to ABMP data in 50 hypertensive patients receiving antibodies to C-end fragment to AT1 receptors for 3 months. (Cardos). The drug was well-tolerated and showeed 24-hour significant decrease of blood pressure at day-time as well as at night-time.
About the Authors
V. Petrov
Volgograd State Medical University
Russian Federation
Russian Federation
A. Kolosova
Volgograd State Medical University
Russian Federation
Russian Federation
S. Tarasov
Volgograd State Medical University
Russian Federation
Russian Federation
L. V . Sabanov
Volgograd State Medical University
Russian Federation
Russian Federation
M. V. Kachanova
Volgograd State Medical University
Russian Federation
Russian Federation
G. Masina
Volgograd State Medical University
Russian Federation
Russian Federation
N. Chepurina
Volgograd State Medical University
Russian Federation
Russian Federation
U. Brel
Volgograd State Medical University
Russian Federation
Russian Federation
T. Chalabi
Volgograd State Medical University
Russian Federation
Russian Federation
O. Epshtein
Volgograd State Medical University
Russian Federation
Russian Federation
S. Nedogoda
Volgograd State Medical University
Russian Federation
Russian Federation
S. Sergeeva
Volgograd State Medical University
Russian Federation
Russian Federation
References
1. Julius S, Nesbitt SD, Egan BM, et al, for the Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; DOI: 10.1056/NEJMoa060838.
2.
3. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; Aug;25(16):1454-70.
4.
5. National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES). Data available at: www.cdc.gov/nchs/nhanes.htm.
6.
7. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289:2560-2572.
8.
9. Зернюкова Е.А. Сравнительная эффективность и фармакодинамика препарата на основе сверхмалых доз антител к С-концевому фрагменту AT1-рецептора ангиотензина II, ингибиторов АПФ и блокаторов рецепторов ангиотензина II у больных гипертонической болезнью. Автореф. дисс. канд. мед. наук, Волгоград, 2005, с. 24.
10.
11. Названова А.В. Экспериментальное обоснование применение кардоса для лечения гипертенической болезни и хронической сердечной недостаточности. Автореф. дисс. канд. мед. наук; Волгоград: 2006: с. 26
12.
13. Эпштейн О.И., Мартюшев А.В., Кудряшова Д.Р., Маркель А.Л., Сергеева С.А., Штарк М.Б. Потенцированные антитела к ангиотензину II и его рецепторам: изучение гипотензивного эффекта. Бюллетень экспериментальной биологии и медицины. Приложение 4. 2002. С. 69-72.
14.
Review
For citations:
Petrov V., Kolosova A., Tarasov S., Sabanov L.V., Kachanova M.V., Masina G., Chepurina N., Brel U., Chalabi T., Epshtein O., Nedogoda S., Sergeeva S. Treatment of hypertension with a very low dose of antibody to C-fragment of type 1 angiotensin II receptor . "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2008;14(3):236-238. (In Russ.) https://doi.org/10.18705/1607-419X-2008-14-3-236-238
Views:
1091
Email this article 